Koh ES, Han K, Nam YS, et al. - Researchers used data from the Korean National Health Insurance Service database from January 2014 to December 2017, to generate real‐world evidence from routine clinical practice explaining the impacts of sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i) on renal outcomes as well as mortality in patients suffering from type 2 diabetes (T2D). Participants were 701,674 patients with T2D, who were split into groups of new‐users of SGLT‐2i and new‐users of other glucose‐lowering drugs (oGLD). Findings of this large nationwide study revealed a lower risk of end‐stage renal disease and all‐cause death in correlation with initiation of SGLT‐2i vs oGLD in Korean patients with T2D.